
New study explores urinary management in people with spinal cord injury
Rethink Medical has contributed to a new study published in Revista ENFURO exploring urinary management and unmet needs among people with spinal cord injury.
Read more
In a thrilling event held at the prestigious Alfredo Kraus Auditorium, our company, Rethink Medical, stood out among the best startups in the final of “Canarias Destination Startup.” After an intense first round of pitch contests, with around 30 promising companies participating, we qualified to compete in the final against the best regional, national, and international startups in the competition.
This year, the competition gained special significance with several finalist companies in the healthcare sector, underscoring the importance of supporting initiatives that aim to improve health and well-being in society.
The stellar performance of Manuel Luque, representative of Rethink Medical, in the final stage of the competition not only captured the attention of the audience and judges but also secured our company the coveted first prize of the event. The accolade includes a cash prize of €10,000, generously awarded by the Cabildo de Gran Canaria, as well as €7,200 in services provided by Intelectium.
This triumph not only solidifies Rethink Medical's position in the business landscape but also highlights the talent and innovation present in the healthcare sector. Congratulations to all participating companies, and we extend our gratitude to the “Canarias Destination Startup” event for providing a platform that drives the growth and visibility of promising startups.

Rethink Medical has contributed to a new study published in Revista ENFURO exploring urinary management and unmet needs among people with spinal cord injury.
Read more
Rethink Medical participated in the 48th Congress of the Spanish Neuroscience Nursing Association, sharing the journey from identifying an unmet need in clinical practice to developing a regulated medical device.
Read more
Rethink Medical reached the minimum target of its 2026 investment round ahead of the initially planned closing date.
Read more